Specialisms:

• Leukemia

• Allogeneic stem cell transplantation

• Tumor immunology

• GVHD

PubMed

LinkedIn

UMC Dept Hematology

UMC Profile

Biography

Prof. Dr. Jürgen Kuball chairs the Department of Hematology at the UMC Utrecht Cancer Centre. Clinical activities focus around acute leukemia and allogeneic stem cell transplantation and he is medical director of the stem cell transplantation program. His research activities focus around tumor immunology and the ATMP development of a next generation of engineered immune cells. Within this context he is scientific co-founder of the UMC Utrecht spin-off company GADETA and holder of multiple patents dealing with engineered immune cells. Kuball is also active member of EBMT and chairs since 2019 the Legal Regulatory Affairs Committee (LRAC) of EBMT.

Research topics

• Chronic complications of immune interventions (GVHD)

• Genetic engineering

• Innate Immune System

• Leukemia

• Next generation allogeneic stem cell transplantations

Current External Activities

Board Activities

• see prof. dr. J.H.E. Kuball - UMC Utrecht

Memberships

• see prof. dr. J.H.E. Kuball - UMC Utrecht

Translational Valorisation

     see prof. dr. J.H.E. Kuball - UMC Utrecht

Personal Fellowships & Awards

• 2001 American Association of Cancer Research-GlaxoSmithKline Scholar in Cancer Research Award

• 2005-2007 Stipendiat der Deutschen Krebshilfe

• 2010 Team Science recognition award” of the Society for Immunotherapy of Cancer, University of Washington, USA

• 2010 VIDI-Laureate ZonMW, The Netherlands

Scientific Publications

Top 7:

• 1.     Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells. Hernandez-Lopez P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, Riillo C, Schwenzel C, Zintchenko M, Johanna I, Nicolasen MJT, Cleven A, Kluiver TA, Millen R, Zheng J, Karaiskaki F, Straetemans T, Clevers H, de Bree R, Stunnenberg HG, Peng WC, Roodhart J, Minguet S, Sebestyen Z, Beringer DX, Kuball J. Nat Immunol 2024 25: 88-101

  2.     CRISPR screens decode cancer cell pathways that trigger γδ T cell detection.
  Mamedov MR , Vedova S, Freimer JW , Sahu AD , Ramesh A, Arce MM, Meringa AD, Ota M, Chen PA, Hanspers K, Nguyen VQ, Takeshima KA, Pritchard JK, Kuball J , Sebestyen Z, Adams EJ , and Marson A.
  Nature. 2023 Sep;621(7977):188-195. doi: 10.1038/s41586-023-06482-x.
  PMID: 37648854 

  3.     Uncovering the mode of action of engineered T cells in patient cancer organoids.
  Dekkers JF, Alieva M, Cleven A, Keramati F, Wezenaar AKL, van Vliet EJ, Puschhof J, Brazda P, Johanna I, Meringa AD, Rebel HG, Buchholz MB, Barrera Román M, Zeeman AL, de Blank S, Fasci D, Geurts MH, Cornel AM, Driehuis E, Millen R, Straetemans T, Nicolasen MJT, Aarts-Riemens T, Ariese HCR, Johnson HR, van Ineveld RL, Karaiskaki F, Kopper O, Bar-Ephraim YE, Kretzschmar K, Eggermont AMM, Nierkens S, Wehrens EJ, Stunnenberg HG, Clevers H*, Kuball J*, Sebestyen Z*, Rios AC*. *shared supervision.
  Nat Biotechnol. 2023 Jan;41(1):60-69. doi: 10.1038/s41587-022-01397-w. Epub 2022 Jul 25 PMID: 35879361 

  4.     Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.
  van Diest E, Hernández López P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, Gumathi Bormin J, van Dooremalen S, Nicolasen MJT, Gatti LCDE, Johanna I, Straetemans T, Sebestyén Z, Beringer DX, Kuball J.
  J Immunother Cancer. 2021 Nov;9(11):e003850. doi: 10.1136/jitc-2021-003850.
  PMID: 34815357

   5.     γ9δ2T cell diversity and the receptor interface with tumor cells.
  Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, de Haas A, Sanders J, Janssen A, Straetemans T, Olive D, Leusen J, Boutin L, Nedellec S, Schwartz SL, Wester MJ, Lidke KA, Scotet E, Lidke DS, Heck AJ, Sebestyen Z, Kuball J.
  J Clin Invest. 2020 Sep 1;130(9):4637-4651. doi: 10.1172/JCI132489.
  PMID: 32484803 

  6.     Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.
  Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J.
  Nat Rev Drug Discov. 2020 Mar;19(3):169-184doi: 10.1038/s41573-019-0038-z. Review.
  PMID: 31492944 

  7. γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.
  Janssen A, Villacorta Hidalgo J, Beringer DX, van Dooremalen S, Fernando F, van Diest E, Terrizi AR, Bronsert P, Kock S, Schmitt-Gräff A, Werner M, Heise K, Follo M, Straetemans T, Sebestyen Z, Chudakov DM, Kasatskaya SA, Frenkel FE, Ravens S, Spierings E, Prinz I, Küppers R, Malkovsky M, Fisch P, Kuball J.
  Cancer Immunol Res. 2020 Apr;8(4):530-543. doi: 10.1158/2326-6066.CIR-19-0513.
  PMID: 32019779